Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

September 2019 Scleroderma News

FDA approves first treatment for patients with rare type of lung disease. The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. FDA News Release, 09/06/2019. (Also see Treatments for Pulmonary Fibrosis and Clinical Trials)

Systemic sclerosis (SSc) medications and risk of scleroderma renal crisis (SRC). Ace inhibitor (ACEi) use at SSC diagnosis was associated with an increased risk for SRC and so SSC patients that require ACEi should be more closely monitored for SRC. PubMed, BMC Nephrol, 2019 Jul 25;20(1):279. (Also see Scleroderma Renal Crisis)

Value of lung diffusing capacity for nitric oxide in systemic sclerosis. Decreased DLCO in the absence of lung restriction does not allow to suspect pulmonary arterial hypertension without fibrosis. PubMed, Physiol Rep, 2019 Aug;7(13):e14149. (Also see Pulmonary Hypertension Diagnosis)

Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis (SSc). Globally available and inexpensive hematological tests, may be associated with vascular and cutaneous manifestations as well as disease activity and severity in SSc. PubMed, Clin Rheumatol, 07/18/2019. (Also see Vascular Involvement)

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator-Initiated, Multicenter, Double-Blind Randomized Placebo-Controlled Trial. In this Phase 2 trial, abatacept was well tolerated, but change in modified Rodnan skin score was not statistically significant. PubMed, Arthritis Rheumatol, 07/24/2019. (Also see Biologic Agents)

Performance of a new quantitative computed tomography index for interstitial lung disease (ILD) assessment in systemic sclerosis (SSc). This new composite CT index for SSc-ILD assessment could be sufficiently sensitive for capturing early lung density changes in visually ILD-free patients. PubMed, Sci Rep, 2019 Jul 1;9(1):9468. (Also see Pulmonary Fibrosis Diagnosis)

A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus (HCMV) in patients with systemic sclerosis (SSc). More prevalent and/or stronger antigen-specific HCMV responses are noted in SSc compared to controls, implying a role of these viral responses in SSc development. PubMed, Clin Immunol, 07/29/2019. (Also see Antibodies)

IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. The regional up-regulation of IL-16 in the skin is not only associated with skin sclerosis, but also with systemic IL-16 activation. PubMed, Rheumatology (Oxford), 08/03/2019. (Also see Skin Fibrosis and Interleukins)

Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features. The results of this study demonstrated that sarcopenia correlates with different nutritional, clinical, and biochemical parameters associated with the worsening of SSc. PubMed, Rheumatol Int, 08/01/2019. (Also see Myopathy and Myositis and Osteoporosis)

Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease (SSc-ILD). Significantly favorable transitions from both ground glass and lung fibrosis ILD patterns to normal lung were found in patients undergoing immunosuppressive treatment for Ssc-ILD. PubMed, Arthritis Rheumatol, 08/20/2019. (Also see Cyclophosphamide and Cellcept)

Can patient-reported symptoms be used to measure disease activity in systemic sclerosis? These results demonstrate that patient-reported symptoms are associated with clinically meaningful changes in disease activity in SSc patients. PubMed, Arthritis Care Res (Hoboken), 08/17/2019. (Also see Scleroderma Symptoms)

Go to Scleroderma Medical News: August 2019

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.